Follow us on Twitter
twitter icon@FreshPatents


Obesity patents

      

This page is updated frequently with new Obesity-related patent applications.

SALE: 320+ Obesity-related patent PDFs



 Chemical compounds and use thereof for improving muscular quality patent thumbnailChemical compounds and use thereof for improving muscular quality
Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity.
Universite Paris 6 Pierre Et Marie Curie


 N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase patent thumbnailN-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency towards gba1, relative to known deoxynojirimycin derivatives of the same (d-gluco, l-ido or d-galacto) configuration.
Universiteit Leiden


 Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like patent thumbnailBiosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

 Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases patent thumbnailUses of bacteroides in treatment or prevention of obesity and obesity-related diseases
Provided are uses of bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases.
Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine


 Methods of treating overweight and obesity patent thumbnailMethods of treating overweight and obesity
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.. .
Orexigen Therapeutics, Inc.


 Amlexanox analogs patent thumbnailAmlexanox analogs
Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.. .
The Regents Of The University Of Michigan


 [7,6]-fused bicyclic antidiabetic compounds patent thumbnail[7,6]-fused bicyclic antidiabetic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


 Antidiabetic bicyclic compounds patent thumbnailAntidiabetic bicyclic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


 Antidiabetic bicyclic compounds patent thumbnailAntidiabetic bicyclic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


 Swallowable capsule and  stimulating incretin production within the intestinal tract patent thumbnailSwallowable capsule and stimulating incretin production within the intestinal tract
Embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc


Dry powder inhaler

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

Functionalized exendin-4 derivatives

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Treating various disorders using trkb agonists

Novel compounds and methods for activating the trkb receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted c5 or c6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
Emory University

Administration of an anti-obesity compound to individuals with renal impairment

The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment..
Arena Pharmaceuticals, Inc.

Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists

Phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same..
Vtv Therapeutics Llc

Compositions for treating or preventing obesity and insulin resistance disorders

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors

Feedback systems and methods enhance obstructive and other obesity treatments by presenting feedback regarding patients' actual eating. An ingestion restricting implant body can be deployed along the gastrointestinal tract.
Intrapace, Inc.

[5,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Deep brain electrode placement and stimulation based on brown adipose tissue temperature

Systems and methods for deep brain electrode placement and deep brain stimulation (dbs) for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a deep brain stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue (bat) may be monitored, e.g., via a supraclavicular temperature sensor implanted in the patient, and used to identify an optimal location of electrode stimulation which causes an increase in bat temperature.
Oregon Health & Science University

A peptide therapy to counteract insulin resistance and type 2 diabetes

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier..

Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a ucp of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance..
Industry-academic Cooperation Foundation, Yonsei University

Hsp90 inhibitors for the treatment of obesity and methods of use thereof

Hsp 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients.
The Children's Medical Center Corporation

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Apparatus for treating obesity

An apparatus for treating obesity in a human or animal mammal patient. The apparatus comprising a first volume filling device segment and a second volume filling device segment.

Method for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Method for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Preparation and use of crystalline beta-d-nicotinamide riboside

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof.
Glaxosmithkline Intellectual Property (no.2) Limited

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Agonists of the apelin receptor and methods of use thereof

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Ex vivo browning of adipose tissue therapy for reversal of obesity and type ii diabetes

Provided are methods, apparatus, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes, by administration to a subject of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues or brown adipose tissue directly converted from white adipose tissue. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue and direct browning of white adipose tissue in a bioreactor rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3d cell aggregates..
The Trustees Of Columbia University In The City Of New York

Novel glucagon analogues

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Pyrazole compounds and methods of making and using same

Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of magl, abhd6, and faah.
The Scripps Research Institute

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Solid oral formulation of fenretinide

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c.
Amgen Inc.

Oxyntomodulin analogue

Provided is an oxyntomodulin analogue. The analogue comprises gcgr and glp-1r dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions.

N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets

Provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases.
The Scripps Research Institute

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache, and pain control, asthma, angina, hypertension, depression, cold, flue and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
Merck Patentgesellschaft

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.. .
Jenrin Discovery

Method and reducing obesity

Method and apparatus for treatment of morbid obesity by placement of a series of flow reduction elements in the small intestine to induce satiety are disclosed. The flow reduction elements restrict the movement of partially digested food and reduce the flow rate through the small intestine which causes the emptying of the stomach and the duodenum to occur slower.

Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety

The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal..
University Of Copenhagen

Intragastric device with expandable portions

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Esculentin-2cha peptide and analogues thereof

The present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia..
University Of Ulster

Antidiabetic substituted heteroaryl compounds

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40.
Merck Sharp & Dohme Corp.

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension. The present invention further provides a d1 agonist with reduced d1r desensitization, a d1 agonist with a reduced β-arrestin recruitment activity relative to dopamine, a d1 agonist interacting significantly with the ser188 but not significantly with the ser202 of a d1r when binding to the d1r, a d1 agonist interacting less strongly the asp103 and interacting less strongly with the ser198 of a d1r when binding to the d1r, and their uses..

Method and instrument for treating obesity

A gastroscopic method of treating obesity of a patient using a device adapted to stretch a part of the stomach wall of said patient. The method comprising the steps of: inserting said device into the stomach of said patient through the esophagus, placing said device in contact with the stomach wall and fixating said device to the stomach wall such that said device can stretch a part of said stomach wall..

Compositions comprising cinnamaldehyde and zinc and methods of using such compositions

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.

Anti-laminin4 antibodies specific for lg1-3

The invention provides antibodies that specifically bind to the lg1-3 modules of the g domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to mcam.
Prothena Biosciences Limited

Composition of plant extract and its pharmaceutical composition and application thereof

Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs..
Caliway Biopharmaceuticals Co., Ltd.

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Technology and methods of on-board vehicle occupant accurate weighing by a simplified weighing apparatus based on weighing moderator and its applications in on-board occupant weighing systems

An on-board vehicle occupant weighing technology includes a simplified vehicle occupant weighing apparatus based on the discovered horwest effect and weighing moderator. The simplified weighing apparatus utilizes a weighing unit connected to the car seat of the vehicle occupant and a further weighing moderator, which provides convenient weighing of the foot part of the occupant's body by the same weighing unit that is connected to the car seat.

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (hpmc) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota..
New York University

Low dose topiramate/phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability.

Application of gpr45 gene

The present invention relates to the field of biotechnology, in particular to application of a gpr45 gene. The present invention discloses, for the first time, a correlation between gpr45 and obesity and also discloses that obesity may be caused if the gpr45 gene is knocked out or the expression of the gpr45 gene is reduced.

Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin a.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases.

Devices and methods for endolumenal treatment of obesity

Devices and methods for forming and securing tissue folds and elongated invaginations in stomach tissue are used as a treatment for obesity. In a first embodiment, a plurality of tissue folds is formed in the fundus region of the stomach.

Stomach-spanning gastric implants

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety.

Organic compositions to treat apoc3-related diseases

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e.g., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.. .
Arrowhead Pharmaceuticals, Inc.

Long-acting single-chain insulin analogues

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a group consisting of gly, ala, pro, or ser; and the remaining c-domain segment is successively derived from the c-domain of igf-ii (rrsr, srrsr, vsrrsr, rvsrrsr, or srvsrrsr; seq id no: 13).
Case Western Reserve University

Peptide yy (pyy) analogues

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.. .
Imperial Innovations Limited

Kv1.3 potassium channel antagonists

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection..
Conogenetix Biosciences Gmbh

Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).. .
The General Hospital Corporation

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for suppressing glucagon secretion of an sglt2 inhibitor

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor.
Astrazeneca Ab

Implantable electroacupuncture treating dyslipidemia and obesity

An exemplary method of treating obesity or dyslipidemia of a patient includes 1) generating, by an electroacupuncture device implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0.05, and 2) applying, by the electroacupuncture device in accordance with the duty cycle, the stimulation sessions to at least one of a saphenous nerve and a peroneal nerve of the patient by way of an electrode array located within the patient at an acupoint corresponding to at least one of the saphenous nerve and the peroneal nerve.. .
Valencia Technologies Corporation

Hmg1 antibody for treating inflammatory conditions

There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ards (acute respiratory distress syndrome), comprising administering an effective amount of a hmg1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of hmg1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms.
The Feinstein Institute For Medical Research

Integrated physical activity level (i-pal) measurement and tracking in adolescents and older teenagers

Described are systems that include at least one sub-system to track, measure, monitor and reward adolescents and young adults for performing daily physical activities, which include before-school, in-school, after-school, sports and activities of daily living. The system offers adolescents the opportunity to track their integrated physical activity level (i-pal) scores over their adolescent years.

Ppar modulators

The present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.. .
FundaÇao Universidade De BrasÍlia

Methods for treating obesity and/or metabolic syndrome

The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
Mesoblast, Inc.

Tetrazolones as inhibitors of fatty acid synthase

Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.. .

Combination therapy for effecting weight loss and treating obesity

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies..

Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products

The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions.
The Hershey Company

Methods, devices, and systems for obesity treatment

In one aspect, a gastric balloon structure includes multiple isolated non-concentric inflatable chambers and a valve system for introducing fluid into each chamber, where the structure assumes, upon inflating, a curved shape conforming to a natural three-dimensional kidney shape of the gastric cavity.. .
Fulfillium, Inc.

Double-acylated glp-1 compounds

The invention relates to a derivative of a glp-1 peptide, which peptide comprises a first lys residue at a position corresponding to position 36 of glp-1(7-37) (seq id no:1), a second lys residue at a position corresponding to position 37 of glp-1(7-37) (seq id no: 1), and a maximum of seven amino acid changes as compared to glp-1(7-37) (seq id no: 1); which derivative comprises two protractors attached to said first and second lys residue, respectively, each via a linker; wherein the protractor is selected from: chem. 1: hooc—c6h4-0-(ch2)y—co—*, and chem.
Novo Nordisk A/s

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Astrazeneca Pharmaceuticals Lp

Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (glp-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome x..
Hyundai Pharm Co., Ltd.

Phenyl-substituted nicotinic ligands, and methods of use thereof

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, lewy body dementia, attention deficit hyperactivity disorder (adhd), parkinson's disease, huntington's disease, tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.. .
Duke University

Antiobesity agent containing walnut extract

To provide an antiobesity agent. An antiobesity agent containing an extract of walnut branches, shells, or leaves as an active ingredient..
Fms Co, Ltd.

Activation of amp-protein activated kinase by oxaloacetate compounds

The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.. .

Treatments for diabetes mellitus and obesity

Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum.

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas

Glp-1/glucagon receptor co-agonists for medical use

The present invention relates to novel glucagon derivatives which are glp-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.. .
Novo Nordisk A/s

Chimeric fibroblast growth factor 19 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.

Urea compounds and their use as enzyme inhibitors

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

Sweetness receptor antagonist

Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .

Peptide analogs for treating diseases and disorders

Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Keybioscience Ag

Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders

The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University

Cycloheptapeptide agents for treatment of cancer and obesity diseases

New anticancer and anti-obesity agents based on cyclic peptide compounds are isolated from the stem barks of maytenus variabilis (loes.) c. Y.
Hong Kong Baptist University

Treatment of obesity and obesity-related disorders by pharmalogical targeting of kv 1.3 potassium channels

Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise shk toxin or a modified shk toxin.
Kineta One, Llc

Synthetic composition for regulating satiety

The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.. .
Glycom A/s

Nitroxides for use in treating or preventing diabetes and obesity

Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes.
Mitos Pharmaceuticals, Inc.

Uses of mito-ob transgenic mice

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.

Sodium glucose co-transporter inhibitors and methods of their use

Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.. .
Lexicon Pharmaceuticals, Inc.

Maternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate maternal nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Composition for inducing differentiation into beige and brown adipocytes and inducing the same

A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of ucp-1 and prdm4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment..
Gyeonggi Institute Of Science & Technology Promoti On

Formulas comprising optimised amino acid profiles

The present invention relates to infant formulas and follow-on formulas containing optimised amino acid profiles, in particular optimised amounts and/or ratios of phenylalanine. The formulas may contain intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof selected based on their ability to provide the formula with an optimised amino acid profile.
N.v. Nutricia

Compositions and methods for controlling the weight of animals

Compositions are provided comprising a balance between lysine and essential amino acids and metabolizable energy. The compositions are useful in methods to prevent or treat obesity in an animal without concomitant loss of lean muscle mass.
Hill's Pet Nutrition, Inc.

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Antidiabetic tricyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Satiation peptide administration

Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides.
University Of Florida Research Foundation, Inc.

Combination of biologically active substances for treatment of hyperglycaemic disorders

The present invention relates to a synergistic composition which comprises (a) phlorizin, and (b) at least one further defined inhibitor of the enzyme lactase-phlorizin hydrolase. In particular, the present invention relates to such a composition for the treatment and/or prophylaxis of a hyperglycemic disease such as obesity, diabetes or a secondary disease associated with diabetes.
Bioactive Food Gmbh

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg

Gastric recycling obesity treatment

obesity treatment apparatus and methods are described herein involving gastric recycling of food are described herein. In one or more embodiments, the gastric recycling apparatus keeps returning chyme to the stomach increasing satiety signals and delaying hunger signals associated with an empty stomach.
Mayo Foundation For Medical Education And Research

Intragastric device

An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g.
Obalon Therapeutics, Inc.

Antagonists of slc38a9 and their use in therapy

The present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh

Compositions and methods for the treatment of diabetes and pre-diabetes

The invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Carbamate compounds and methods of making and using same

This disclosure provides compounds and compositions which may be modulators of magl and/or abhd6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition..
Abide Therapeutics, Inc.

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Composition comprising scirpusin a and scirpusin b and anti-obesity potential thereof

Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.. .

Composition of mangifera indica and making and using thereof

The invention relates to a herbal composition derived from mangifera indica. Methods of making and using the composition for the management of obesity are also contemplated..

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv

Treatment of metabolic disorders in equine animals

A sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal..
Boehringer Ingelheim Vetmedica Gmbh

Nucleotide and amino acid sequences relating to respiratory diseases and obesity

This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby.
Oscient Pharmaceuticals Corporation

Bicyclic derivatives and pharmaceutical composition including the same

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (sglts) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the sglt activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type i diabetes mellitus) and non-insulin-dependent diabetes (type ii diabetes mellitus), diabetic complications, and obesity.. .
Hanmi Pharm. Co., Ltd.

Fumagillol heterocyclic compounds and methods of making and using same

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided.
Zafgen, Inc.

Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions

The invention relates to the use of tomatoes for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. Provided is a tomato plant, fruit, fragment or extract thereof for use in a method for preventing weight gain, and/or inhibiting, preventing or ameliorating a disease condition associated with adipogenesis in a mammal, wherein the tomato is a ripening-impaired mutant tomato, such as a ripening inhibitor (rin), nonripening (nor), and/or never ripe (nr) gene mutant tomato.
Green4health B.v.

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Activated soy pod fiber

The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, ibd, and gastrointestinal dysbiosis..
Microblome Therapeutics Llc

Anti-reflux or anti-obesity prosthesis

A prosthesis (14) that is useful as an anti-reflux device or an anti-obesity device within a gastro-intestinal tract of a living organism, such as a human, comprises an elastic portion including a helical elastic spring (15) embedded in a biocompatible material.. .
Biomedix S.a.

Variable size intragastric implant devices

Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight.
Apollo Endosurgery, Inc.

Peptides hormone analogues derivable from preproglucagon

Peptide hormone analogues of the formula x-v are provided herein, wherein x is a glucagon analogue or a glp1 analogue, and v is a c-terminal extension amino acid sequence comprising at least four amino acid residues, at least three of said residues being his. Also provided herein are pharmaceutical compositions comprising said analogues, and methods of using said analogues for the treatment of conditions such as obesity and diabetes..
Imperial Innovations Limited

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.. .
The Board Of Regents Of The University Of Texas System

Ghrelin o-acyltransferase inhibitors

Small molecule ghrelin o-acyltransferase inhibitors found using an assay to detect ghrelin o-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin o-acyltransferase inhibitors and detection via high performance liquid chromatography. The newly discovered class of synthetic triterpenoids efficiently inhibits ghrelin acylation by goat and function as covalent reversible inhibitors of goat.
Syracuse University

Methods of treating an overweight or obese subject

The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.. .
Zafgen, Inc.

Apparatus and methods for treatment of morbid obesity

Apparatus and methods are described for treatment of morbid obesity using minimally invasive techniques. The apparatus includes a system of components that may be used separately or in combination for effectively reducing stomach volume, bypassing a portion of the stomach and/or small intestines, reducing nutrient absorption in the stomach and/or small intestines and/or depositing minimally or undigested food farther than normal into the intestines, thereby stimulating intestinal responses.
Valentx, Inc.

Intragastric device for treating obesity

A gastrointestinal device for treating obesity includes a three-dimensional porous structure configurable between a compressed pre-deployment configuration to facilitate delivery and an expanded post-deployment configuration. The porous structure includes a first opening at its proximal end and a larger second opening at its distal end.
Synerz Medical, Inc.

Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin

This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression.
Mayo Foundation For Medical Education And Research

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Novel glucagon analogues

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Peptide having efficacy for remedying hypopigmentation and inhibiting adipogenesis, and use of same

A peptide formed from the amino acid sequence of seq id no: 1 or seq id no: 2, according to the present invention, shows a melanogenesis increment activity and an adipogenesis inhibitory activity. A peptide of the present invention, by increasing phosphorylation of mitf, which is a transcription factor for increasing a tyrosinase expression, and creb for increasing an mitf expression, consequently increases a tyrosinase expression and ultimately increases melanin synthesis.
Caregen Co., Ltd.

Aromatic heterocyclic compound

The compound represented by the general formula: wherein ring a is benzene which may be substituted and the like; ring b is benzene which may be substituted and the like; x is a single bond and the like; y is alkyl which may be substituted and the like; z is cr1 or nitrogen atom; r1 is hydrogen and the like; r2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.. .
Mitsubishi Tanabe Pharma Corporation

Mitochondrial-derived peptide mots3 regulates metabolism and cell survival

Mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein..
The Regents Of The University Of California

Gastric device and use thereof

The present invention provides a low-risk, unobtrusive and noninvasive method and device for treatment of obesity and eating disorders. In embodiments, the device is a gastric device suitable for placement in a stomach of a subject.
The Johns Hopkins University

Method for diagnosing hepatic fibrosis

The present invention concerns methods, in particular in vitro methods, for diagnosing liver fibrosis in a subject suffering from obesity, or for selecting a subject suffering from obesity for liver biopsy or for treatment. The present invention also pertains to methods for screening a probiotic, a prebiotic, a chemical compound or a biological compound suitable for preventing and/or treating liver fibrosis..
FundaciÓ Institut D'investigaciÓ BiomÈdica De Girona Dr. Josep Trueta

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
The Metrohealth System

Oxaspiro[2.5]octane derivatives and analogs

The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.. .
Zafgen, Inc.

Radiosurgical neuromodulation devices, systems, and methods for treatment of behavioral disorders by external application of ionizing radiation

Radiosurgical techniques and systems treat behavioral disorders (such as depression, obsessive-compulsive disorder (“ocd”), addiction, hyperphagia, and the like) by directing radiation from outside the patient toward a target tissue within the patient's brain, typically without imposing surgical trauma. The target will often be included in a neural circuit associated with the behavioral disorder.

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Mangifera indica as a sirtuin 1 activating agent

The invention relates to a mangifera (mango) indica preparation as sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developing obesity, type ii diabetes, elevated blood lipid levels, artheriosclerosis and cardiovascular diseases, as well as a cell and dna protector..
Vital Solutions Swiss Ag

Sitagliptin tannate complex

The present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure..
Merck Sharp & Dohme Corp.

Targeted nanoparticle compositions and methods of their use to treat obesity

Nanoparticles having a positive feedback delivery system include an agent specific for a target in combination with a target inducing agent. Upon administration to a subject, the targeting moiety on the nanoparticles binds to available targets in the subject.
Massachusetts Institute Of Technology

Macrocyclic ghrelin receptor modulators and methods of using the same

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, ghs-r1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein.
Ocera Therapeutics, Inc.

Functional food formula analysis system for personalized body weight management

A functional food formula analysis system for personalized body weight management includes a user input unit, a body constitution analysis data unit, a functional food data unit, an analysis server unit, and an analysis result storage unit. The analysis server unit is connected to the other units and is configured for retrieving personal data, personal genetic data, and obesity-associated body constitution data and performing data comparison, exchange, and integration on those data in order to output a personalized functional food formula report to be stored in the analysis result storage unit.
Union Applied Gene Inc.

Anti-obesity compounds derived from neuromedin u

The invention relates to polypeptides referred to herein as nmu analog peptides. Nmu analog peptides regulate energy homeostasis..
The Regents Of The University Of California

Heteroaryl compounds and methods of use thereof

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharamaceuticals Inc.

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Novel lactic acid bacterium and use thereof

A new lactobacillus mali that can be used for preventing or treating a metabolic syndrome is provided. A method for preventing or treating obesity, diabetes or a complication of diabetes by using the lactobacillus mali is also provided..
National Taiwan University

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including alzheimer's disease, parkinson's disease, dyskinesias, tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia..
Duke University

Methods, devices, and systems for obesity treatment

Methods and systems for detecting wall breach in inflatable prostheses rely on intrusion of a body fluid or inflation medium to electrically alter a signaling circuit. In one embodiment, an open portion of a circuit is closed to enable or modify a transmitted signal in another embodiment, electrical current is generated to power an electrical transmission..
Fulfillium, Inc.

Tai chi sword brush

This invention is intended to address the american obesity crisis by combing three of china's treasured art forms, calligraphy, brush painting and tai chi, into an easy to use exercise implement. The sword brush utilizes the whole body moving as one to stimulate healing energy, or qi.

Chimeric fibroblast growth factor 21 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf21 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to indanone compounds. The indanone compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Cyclohexenyl compounds, compositions comprising them and methods

The present invention is directed to phenyl substituted cyclohexenyl compounds, compositions comprising them and uses thereof for the preparation of medicaments for the treatment of obesity and any disease or disorder associated therewith, for reduction in food consumption, and for the treatment of inflammation and disorders associated therewith.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Swallowable capsule and stimulating incretin production within the intestinal tract

Embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Dietary compositions for reducing blood glucose levels and for weight management

The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.

Gastrointestinal tract bypass devices

Devices and methods can be used for the endoscopic treatment of conditions such as obesity and metabolic diseases. For example, this document provides devices and methods for bypassing portions of the gastrointestinal tract to reduce nutritional uptake.
Mayo Foundation For Medical Educationand Research

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects.
Hanmi Science Co., Ltd

Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The substituted fused heterocyclic compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them..

Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to isoindolinone compounds. The isoindolinone compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Fat removal device and obesity treatment

A medical device for treatment for overweight or obesity is presented. The medical device is attached or implanted in patient's target body organs, wherein in each one of the device attachments, or daily in the case of long continuous attachment, the device removes up to 100 grams of energy containing materials from the body.

Chemosensory receptor ligand-based therapies

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.

Free raptor reduces aging- and obesity-induced fatty liver

The present invention also provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride. .

Sorcs1 for the treatment of obesity

The present invention relates to sorcs1-like agents, including sorcs1, nucleic acid molecule encoding expression of sorcs1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing sorcs1 and said fragments, for the treatment of obesity.. .
Aarhus Universitet

Compositions and methods for reducing chronic low-level inflammation

The invention relates to compositions and methods for reducing chronic low-level inflammation associated with chronic conditions. Specifically, the invention relates to compositions of hydrophobic derivatives of aspirin and/or hydrophobic derivatives of sesamol in combination with eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and their methods for reducing chronic low-level inflammation associated with chronic conditions including obesity, metabolic syndrome, diabetes, cardiovascular disease, cancer, auto-immune disorders, ocular and neurological disorders in a mammal..

Nuclear receptor binding agents

The present application relates to methods of treating, preventing, delaying the onset of, reducing the incidence of, or reducing the severity of fibrosis, obesity and conditions associated with post-menopausal obesity.. .
Gtx, Inc.

Device and endoluminal therapy

A device and method for selectively engaging or penetrating a layer of a luminal organ wall where the luminal organ wall has a plurality of layers including an outermost layer and an innermost layer adjacent to the lumen of the organ. The device and method select one of the plurality of layers of the organ wall other than the innermost layer and deploy from within the lumen of the organ a tissue device through the innermost layer to a specific depth to engage or penetrate the selected one of the plurality of layers.

Exendin-4 derivatives as selective peptidic dual glp-1/glucagon receptor agonists

The present invention relates to dual glp-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Novel peptides and peptide derivatives and uses thereof

The invention relates to cholecystokinin (cck) derivatives of the general formula i: p-l-x1-x2-x3-gly-trp-x6-dmeasp-x8-nh2, wherein p is chem. 1: hooc—(ch2)x—co—*, wherein x is an integer in the range of 12-18; l is absent, or l comprises at least one linker element selected from chem.
Novo Nordisk A/s

Green coffee bean extract and method thereof

An extract from green coffee beans is disclosed which contains polyphenols and bioactive compounds e.g. Chlorogenic acids in a significantly higher concentration (70-80%) than in extracts of prior art methods (40-50%).

Small molecule inhibitors of xbp1 splicing

Small molecule inhibitors of xbp1 splicing by ire1α are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.. .
Georgetown University

Mirna modulators of thermogenesis

Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery.
Aptamir Therapeutics, Inc.

Partially saturated tricyclic compounds and methods of making and using same

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.
Zafgen, Inc.

Nutritional compositions with phospholipids

The present invention relates to a nutritional composition such as an infant formula comprising phospholipids in an amount of at least 300 mg/l. Bioactive compounds may preferably be added to the nutritional composition.
Nestec S.a.

Composition and methods for the prevention and treatment of diet-induced obesity

The invention provides a method for treating or preventing diet-induced obesity in a subject comprising administering an agent in an effective amount so that expression or activity of the p2y2 receptor is decreased or inhibited in the subject thereby treating or preventing diet-induced obesity in the subject.. .

Methods and compositions for treating obesity

The present invention provides anti-ghrelin antibodies or antigen-binding molecules that are capable of degrading ghrelin and inhibiting ghrelin-mediated cellular activities. Also provided in the invention are therapeutic applications of combinations of these antibodies, e.g., to treat or prevent obesity..
The Scripps Research Institute

Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain

The invention provides a method for reducing or preventing body weight gain in a subject comprising administering to the subject enolase 1 (eno1). The invention also provides methods of treating obesity, and of reducing body weight in a subject afflicted with an overweight condition, comprising administering to the subject enolase 1 (eno1).
Berg Llc

Composition for treatment or prevention of obesity, containing water extracts of fomitella fraxinea

The present invention relates to a composition for the treatment or prevention of obesity, the composition containing water extracts of fomitella fraxinea as an active ingredient, and to a medicine and a dietary supplement, containing the extracts.. .
Kyeongsangbuk-do

Compounds for the treatment of obesity and methods of use thereof

Weight loss agents include compounds defined by formula i or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is withaferin a.
The Children's Medical Center Corporation

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Methods and instruments for treating obesity

The invention relates surgical abdominal methods of treating obesity in a patient by implanting a volume filling device that, when implanted in a patient, reduces the food cavity in size by a volume substantially exceeding the volume of the volume filling device. Also disclosed is a laparoscopic instrument for providing a volume filling device to be invaginated in the stomach wall of a human patient to treat obesity..

Metabolic imprinting

The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof.
Nestec S.a.

Nutritional composition

A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition..
Ajinomoto Co., Inc.

Computerized estimating levels of obesity in an insured population

A computerized system and method for estimating levels of obesity in an insured population using claims data. The model uses health risk assessment data comprising age, height, and weight information as well as information about health conditions and health behaviors for a member population.
Humana Inc.

Compositions and methods for treating obesity

The present invention provides anti-ghrelin antibodies or antigen-binding molecules that are capable of sequestering ghrelin and inhibiting ghrelin-mediated cellular activities. Also provided in the invention are therapeutic applications of combinations of these antibodies, e.g., to treat or prevent obesity..
The Scripps Research Institute

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cgmp-dependent phosphodiesterases.. .
Synergy Pharmaceuticals, Inc.

Antioxidant-enriched fruit extracts and uses thereof in the treatment and prevention of diabetes and obesity

A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria serratia vaccinii. The antioxidant-enriched composition is capable of decreasing plasma glucose levels, increasing circulating adiponectin levels and decreasing hyperphagia in a subject..
University Of Ottawa

Synthetic composition for treating metabolic disorders

The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (hmos).. .
Glycom A/s

Antibody specifically binding to glp-1r and fusion protein thereof with glp-1

Disclosed in the present invention is an antibody specifically binding to glp-1r and a fusion protein thereof with glp-1. The fusion proteins can effectively bind to a human glp-1r receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof..
Gmax Biopharm Llc.

Method to prepare hirsutella sinensis polysaccharides possessing anti-obesity properties and uses thereof

The present invention provides a method to prepare polysaccharides from hirsutella sinensis. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity..
Chang Gung Biotechnology Corp.

Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

Treatment of metabolic disorders in canine animals

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or syndrome x (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.. .
Boehringer Ingelheim Vetmedica Gmbh

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Methods for reducing childhood obesity and for calculating childhood obesity risk

The present disclosure provides personalized methods for preventing and/or reducing early childhood obesity that are based upon identifying a child's individual risk of obesity and tailoring methods to prevent or reduce obesity. The methods may be based on early inception (e.g., third trimester of pregnancy), anticipatory guidance (e.g., prior to an infant reaching a specific developmental stage), sequential guidance, and nutritionally and developmentally appropriate dietary and parental feeding behaviors guidance, all specifically targeting factors that have been associated with childhood obesity.
Nestec S.a.

Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis

The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting acyl-coa: cholesterol acyltransferase 1 (acati) activity or expression in myeloid cells.. .
Trustees Of Dartmouth College

Fused heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (i): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided..
Takeda Pharmaceutical Company Limited

Solid forms comprising(-)-o-desmethylvenlafaxine and uses thereof

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-o-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders..
Sunovion Pharmaceuticals Inc.

Devices for and methods of treatment of metabolic syndromes

Devices for and methods of treatment of metabolic syndromes are disclosed. Namely, the presently disclosed devices and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic syndromes.
The Johns Hopkins University

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Tricyclic compounds and methods of making and using same

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.
Zafgen, Inc.

Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of formulation i, and its method on in vitro and in vivo systems.

Method to prepare ganoderma lucidum polysaccharides possessing anti-obesity properties and uses thereof

The present invention provides a method to prepare polysaccharides from ganoderma lucidum. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity..
Chang Gung Biotechnology Corp.

Glucagon analogues

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes.
Boehringer Ingelheim International Gmbh

Novel glucagon analogues

The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (i): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided..
Takeda Pharmaceutical Company Limited

Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University

Sweetener composition for preventing and improving obesity, containing glycolysis inhibitor ingredient

The present invention relates to a sweetener composition for preventing or treating obesity containing, as active ingredients, a glucose or d-fructose absorption inhibiting component and a sugar hydrolysis inhibiting sugar or sugar alcohol.. .
Cj Cheiljedang Corporation

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Transgenic mouse models for mc4r

There are provided herein transgenic non-human animals and cells comprising a transgene encoding either a mutated human melanocortin type-4 receptor (hmc4r) protein, wherein the mutated protein is misfolded and retained intracellularly, or a wild-type human melanocortin type-4 receptor (hmc4r) protein. Transgenes and targeting constructs used to produce such transgenic animals and cells are also provided, as well as methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling obesity..
Universite De Montreal

Methods and compositions for using cinnamaldehyde and zinc for weight management

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.

Antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Michael Miller

Lipidated peptides as anti-obesity agents

Lipidated peptides, analogs of both forms of the prolactin-releasing peptide. Prrp31 and prrp20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration.
Ustav Organicke Chemie A Biochemie Akademie Ved Cr, V.v.i

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Composition comprising okra for use in reducing dietary fat absorption

Composition comprising (optionally processed) edible parts of an okra plant species for use in reducing dietary fat absorption in a subject or for use in treating or preventing obesity and/or for use in treating or preventing a metabolic disease such as metabolic syndrome, or for managing the weight of a subject, by binding dietary fat in the subject's stomach.. .
Inqpharm Group Sdn Bhd

Novel human genes relating to respiratory diseases and obesity

This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
Oscient Pharmaceuticals Corporation

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Tricyclic pyrazole sulphonamide compounds and methods of making and using same

The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.
Zafgen, Inc.

Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Compositions and methods for diagnosis and treatment of metabolic syndrome

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
Government Of The United States Of America, As Represented By The Secretary Of The Navy

Apparatus for treating gerd comprising a stimulation device

The present invention relates to a reflux disease treatment apparatus, apparatus, comprising an implantable movement restriction device that maintains cardia in the correct position and an implantable stimulation device adapted to engage with the cardia sphincter of a patient. The invention further comprises a control device for controlling the stimulation device to stimulate the cardia sphincter.

Systems, devices, and methods for forming anastomoses

The invention relates to deployable magnetic compression devices and systems and methods for the deployment of such magnetic compression devices. The magnetic compression devices are particularly useful for creating anastomoses, e.g., in the gastrointestinal tract.
Gi Windows, Inc.

Complete nutritional powder and preparation method thereof

The invention discloses complete nutritional powder and a preparation method thereof. The powder is characterized by containing vitamin b1, vitamin b2, vitamin b6, pantothenic acid, niacin, vitamin b12, vitamin c, vitamin a, vitamin k, vitamin d, vitamin e, biotin, folic acid, calcium, magnesium, iron, zinc, selenium, chromium, copper, manganese, corn fiber powder, inulin, isolated soy protein powder, black bean extract, brazil mushroom extract, soya bean lecithin, semen phaseoli extract, l-carnitine, β carotene, lycopene, citrus extract, vanadium, acerola cherry extract, grape seed extract, maltodextrin, essence, aspartame, and acesulfame.

Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

This invention is in the area of improved anti-ap2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone ap2/fabp4 (referred to as “ap2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for ap2 mediated disorders are disclosed in which serum ap2 is targeted and the biological activity of ap2 is neutralized or modulated using low-binding affinity ap2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease..
Ucb Biopharma Sprl

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Nutritional composition comprising hydrolyzed protein

Liquid nutritional compositions include specific combinations of protein, carbohydrate, and fat for the nutritional support of individuals with particular needs, such as individual suffering from obesity. The compositions comprise a source of at least one omega-6 fatty acid and a source of at least one omega-3 fatty acid with a ratio of omega-6 to omega-3 of 1:5 to 1:1.
Abbott Laboratories

Maternal vitamin b12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Methods of treating cancer and other disorders

Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1h-indazole-4,7-dione or an analog thereof.
Wake Forest University Health Sciences

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.



Obesity topics:
  • Hypertension
  • Inflammation
  • Nephropathy
  • Syndrome X
  • Cardiovascular
  • Endometrial
  • Polycystic Ovarian Disease
  • Prostate Cancer
  • Uterine Fibroids
  • Restenosis
  • Breast Disease
  • Dysfunctional Uterine Bleeding
  • Cardiovascular Disease
  • Aldosterone
  • Dyslipidemia


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Obesity for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Obesity with additional patents listed. Browse our RSS directory or Search for other possible listings.


    3.455

    file did exist - file did put11071

    5 - 1 - 252